125 related articles for article (PubMed ID: 28574706)
1. Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
Helal CJ; Arnold EP; Boyden TL; Chang C; Chappie TA; Fennell KF; Forman MD; Hajos M; Harms JF; Hoffman WE; Humphrey JM; Kang Z; Kleiman RJ; Kormos BL; Lee CW; Lu J; Maklad N; McDowell L; Mente S; O'Connor RE; Pandit J; Piotrowski M; Schmidt AW; Schmidt CJ; Ueno H; Verhoest PR; Yang EX
J Med Chem; 2017 Jul; 60(13):5673-5698. PubMed ID: 28574706
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
Mikami S; Nakamura S; Ashizawa T; Nomura I; Kawasaki M; Sasaki S; Oki H; Kokubo H; Hoffman ID; Zou H; Uchiyama N; Nakashima K; Kamiguchi N; Imada H; Suzuki N; Iwashita H; Taniguchi T
J Med Chem; 2017 Sep; 60(18):7677-7702. PubMed ID: 28796496
[TBL] [Abstract][Full Text] [Related]
3. Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
Mikami S; Sasaki S; Asano Y; Ujikawa O; Fukumoto S; Nakashima K; Oki H; Kamiguchi N; Imada H; Iwashita H; Taniguchi T
J Med Chem; 2017 Sep; 60(18):7658-7676. PubMed ID: 28759228
[TBL] [Abstract][Full Text] [Related]
4. [1,2,4]Triazolo[1,5-
Tresadern G; Velter I; Trabanco AA; Van den Keybus F; Macdonald GJ; Somers MVF; Vanhoof G; Leonard PM; Lamers MBAC; Van Roosbroeck YEM; Buijnsters PJJA
J Med Chem; 2020 Nov; 63(21):12887-12910. PubMed ID: 33105987
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.
Zhang C; Feng LJ; Huang Y; Wu D; Li Z; Zhou Q; Wu Y; Luo HB
J Chem Inf Model; 2017 Feb; 57(2):355-364. PubMed ID: 28055196
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.
Helal CJ; Arnold E; Boyden T; Chang C; Chappie TA; Fisher E; Hajos M; Harms JF; Hoffman WE; Humphrey JM; Pandit J; Kang Z; Kleiman RJ; Kormos BL; Lee CW; Lu J; Maklad N; McDowell L; McGinnis D; O'Connor RE; O'Donnell CJ; Ogden A; Piotrowski M; Schmidt CJ; Seymour PA; Ueno H; Vansell N; Verhoest PR; Yang EX
J Med Chem; 2018 Feb; 61(3):1001-1018. PubMed ID: 29293004
[TBL] [Abstract][Full Text] [Related]
7. Identification of lead BAY60-7550 analogues as potential inhibitors that utilize the hydrophobic groove in PDE2A: a molecular dynamics simulation study.
Kumar J; Umar T; Kausar T; Mobashir M; Nayeem SM; Hoda N
J Mol Model; 2017 Jan; 23(1):7. PubMed ID: 27966018
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography.
Schröder S; Wenzel B; Deuther-Conrad W; Teodoro R; Egerland U; Kranz M; Scheunemann M; Höfgen N; Steinbach J; Brust P
Molecules; 2015 May; 20(6):9591-615. PubMed ID: 26016549
[TBL] [Abstract][Full Text] [Related]
9. Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).
Trabanco AA; Buijnsters P; Rombouts FJ
Expert Opin Ther Pat; 2016 Aug; 26(8):933-46. PubMed ID: 27321640
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
Mikami S; Kawasaki M; Ikeda S; Negoro N; Nakamura S; Nomura I; Ashizawa T; Kokubo H; Hoffman ID; Zou H; Oki H; Uchiyama N; Hiura Y; Miyamoto M; Itou Y; Nakashima M; Iwashita H; Taniguchi T
Chem Pharm Bull (Tokyo); 2017; 65(11):1058-1077. PubMed ID: 29093293
[TBL] [Abstract][Full Text] [Related]
11. Target Engagement of a Phosphodiesterase 2A Inhibitor Affecting Long-Term Memory in the Rat.
Gu G; Scott T; Yan Y; Warren N; Zhang A; Tabatabaei A; Xu H; Aertgeerts K; Gomez L; Morse A; Li YW; Breitenbucher JG; Massari E; Vivian J; Danks A
J Pharmacol Exp Ther; 2019 Sep; 370(3):399-407. PubMed ID: 31253692
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.
Redrobe JP; Jørgensen M; Christoffersen CT; Montezinho LP; Bastlund JF; Carnerup M; Bundgaard C; Lerdrup L; Plath N
Psychopharmacology (Berl); 2014 Aug; 231(16):3151-67. PubMed ID: 24577516
[TBL] [Abstract][Full Text] [Related]
13. The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.
Forster AB; Abeywickrema P; Bunda J; Cox CD; Cabalu TD; Egbertson M; Fay J; Getty K; Hall D; Kornienko M; Lu J; Parthasarathy G; Reid J; Sharma S; Shipe WD; Smith SM; Soisson S; Stachel SJ; Su HP; Wang D; Berger R
Bioorg Med Chem Lett; 2017 Dec; 27(23):5167-5171. PubMed ID: 29113762
[TBL] [Abstract][Full Text] [Related]
14. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models.
Nakashima M; Suzuki N; Shiraishi E; Iwashita H
Behav Brain Res; 2019 Dec; 376():112192. PubMed ID: 31521738
[TBL] [Abstract][Full Text] [Related]
15. A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors.
Wunder F; Gnoth MJ; Geerts A; Barufe D
Mol Pharm; 2009; 6(1):326-36. PubMed ID: 19049345
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.
Redrobe JP; Rasmussen LK; Christoffersen CT; Bundgaard C; Jørgensen M
Eur J Pharmacol; 2015 Aug; 761():79-85. PubMed ID: 25941078
[TBL] [Abstract][Full Text] [Related]
17. Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation.
Hamza A; Zhan CG
J Phys Chem B; 2009 Mar; 113(9):2896-908. PubMed ID: 19708117
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in
Nakashima M; Imada H; Shiraishi E; Ito Y; Suzuki N; Miyamoto M; Taniguchi T; Iwashita H
J Pharmacol Exp Ther; 2018 Apr; 365(1):179-188. PubMed ID: 29440309
[TBL] [Abstract][Full Text] [Related]
19. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631.
Maehara S; Arakawa K; Hoshida K; Nagasue H; Chida N; Nakao K; Furusako S
Eur J Pharmacol; 2017 Sep; 811():110-116. PubMed ID: 28587776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
